News

Technology News

Quinnova Launches Hydrating Topical Foam

Tuesday, January 06, 2009 5:04:00 AM PDT | VentureDeal Staff
Newtown, Pennsylvania  --  Pharmaceutical company Quinnova Pharmaceuticals announced the launch of a new treatment for hyperkeratotic medical conditions.

Called Salvax, the hydrating topical foam is designed to treat conditions such as keratosis pilaris, psoriasis and xerosis. The product helps to restore the skin barrier, hydrate and protect the skin.

“Salvax (Hydrating Topical Foam) is a great addition to our current portfolio of products based on Proderm TechnologyTM,” said Jeffrey S. Day, Quinnova’s President & CEO. “When physicians are treating hyperkeratotic conditions, they can choose their product or active ingredient of choice — either Salvax (Hydrating Topical Foam) or Hydro 40® Foam. Both products share the therapeutic and cosmetic benefits of Proderm TechnologyTM while providing an active ingredient of the physician’s preference (urea 40% or salicylic acid 6%).”

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1